4.7 Article

Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer

期刊

CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 70, 期 10, 页码 2937-2950

出版社

SPRINGER
DOI: 10.1007/s00262-021-02894-8

关键词

FPR1; CCRT; ICD; DAMP; Cancer immunity

资金

  1. China Medical University Hospital [DMR-108-221]
  2. Ministry of Science and Technology [MOST106-2314-B-039-005]
  3. China Medical University Hospital Cancer Research Center of Excellence (Taiwan) [MOHW109-TDU-B-212-134024]
  4. Ministry of Science and Technology (Taiwan) [MOST107-2314-B-039-027-MY3, MOST107-2314B-039-057-MY3]

向作者/读者索取更多资源

Immunosurveillance and immunoscavenging induced by preoperative chemoradiotherapy (CCRT) can enhance local control and improve survival rates in locally advanced rectal cancer patients. This study focused on the impact of different genotypes of pattern recognition receptors (PRRs) on therapeutic efficacy in LARC patients receiving CCRT. The findings suggest that the FPR1 genotype may play a role in CCRT-induced anticancer immunity, affecting T lymphocyte migration and infiltration, and could serve as a biomarker for chemo- and radiotherapy outcomes.
Immunosurveillance and immunoscavenging prompted by preoperative chemoradiotherapy (CCRT) may contribute to improve local control and increase survival outcomes for patients with locally advanced rectal cancer (LARC). In this study, we investigated several genotypes of pattern recognition receptors (PRRs) and their impact on therapeutic efficacy in LARC patients treated with CCRT. We found that homozygosis of formyl peptide receptor 1 (FPR1) (E346A/rs867228) was associated with reduced 5-year overall survival (OS) by Kaplan-Meier analysis (62% vs. 81%, p = 0.014) and multivariate analysis [hazard ratio (HR) = 3.383, 95% CI = 1.374-10.239, p = 0.007]. Moreover, in an animal model, we discovered that the FPR1 antagonist, Boc-MLF (Boc-1), reduced CCRT therapeutic efficacy and decreased cytotoxic T cells and T effector memory cells after chemoradiotherapy treatment. Pharmacologic inhibition of FPR1 by Boc-1 decreased T lymphocyte migration to irradiated tumor cells. Therefore, these results revealed that the FPR1 genotype participates in CCRT-elicited anticancer immunity by reducing T lymphocytes migration and infiltration, and that the FPR1-E346A CC genotype can be considered an independent biomarker for chemo- and radiotherapy outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据